BNP Paribas Financial Markets Has $129,000 Stock Holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM)

BNP Paribas Financial Markets boosted its stake in shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) by 1,248.6% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 6,743 shares of the company’s stock after buying an additional 6,243 shares during the period. BNP Paribas Financial Markets’ holdings in Contineum Therapeutics were worth $129,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of CTNM. Sandia Investment Management LP acquired a new position in shares of Contineum Therapeutics in the second quarter valued at approximately $88,000. Rhumbline Advisers acquired a new position in Contineum Therapeutics in the 2nd quarter worth $118,000. Bank of New York Mellon Corp bought a new position in Contineum Therapeutics during the 2nd quarter worth about $356,000. Driehaus Capital Management LLC bought a new position in Contineum Therapeutics during the 2nd quarter worth about $1,174,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Contineum Therapeutics in the 2nd quarter valued at about $2,642,000.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on CTNM shares. Robert W. Baird started coverage on Contineum Therapeutics in a research report on Tuesday, October 22nd. They set an “outperform” rating and a $32.00 price objective for the company. Royal Bank of Canada reduced their price target on Contineum Therapeutics from $32.00 to $31.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Finally, Baird R W upgraded shares of Contineum Therapeutics to a “strong-buy” rating in a report on Tuesday, October 22nd. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $29.25.

Contineum Therapeutics Price Performance

Shares of NASDAQ CTNM opened at $13.75 on Thursday. The stock has a 50 day moving average price of $15.86 and a 200 day moving average price of $17.71. Contineum Therapeutics, Inc. has a 52 week low of $12.33 and a 52 week high of $22.00.

Contineum Therapeutics (NASDAQ:CTNM) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.01. As a group, sell-side analysts predict that Contineum Therapeutics, Inc. will post -2.01 earnings per share for the current year.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).